Today Ovation.io, the parent company behind Ovation Service Lab and Ovation Research, announced a US$1.5 million investment led by StageDotO and including existing investors. The funding will help Ovation.io to build on the success of both its products in supporting the work of the most forward-thinking biomedical labs, companies, and consortia in both clinical and pre-clinical scientific research. The recent announcement highlights the work of one Ovation Research customer, the iGeneTrain consortium based at the University of Pennsylvania, which relies on global collaboration around shared data and analyses in an effort to improve the understanding of organ transplant outcomes. Get in touch with Ovation.io to learn more about the problems that it solves every day for scientific researchers throughout the world.